Case series of complex therapy of hemoblastosis in the context of COVID-19

Jamilya Saparbay 1 * , Vadim Kemaykin 1, Ruzal Vildanova 1, Azat Karabekov 1, Zhandos Burkitabayev 1
More Detail
1 Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Nur-Sultan, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, In press.


The COVID-19 pandemic is a problem of a global scale, and it has an importance in modern oncology and hematology. Patients with cancer are at high risk of getting infected with COVID-19. Diagnosis of coronavirus infection in this group of patients delays the chemotherapy. A break between courses of treatment, as well as a complete cancellation of therapy, can increase the mortality of patients from oncohematological diseases. Between June 2020 and October 2020 300 patients with hemoblastosis were treated in our center. Among them 19 patients developed COVID-19 infection. The mean age of this group of patients was 43±16; 8 female; 11 male. Hepatitis B + hepatitis D infection was the most common cause of end-stage liver disease (21 cases; 32.8%).  Patients with multiple myeloma - 32%; acute myeloid leukemia - 26%; acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia - 26%; chronic lymphocytic leukemia - 5%. Treatment was carried out following the protocols for the diagnosis and treatment of hemoblastosis and concomitant COVID-19 infection accepted in Kazakhstan. Here we present the first report of complex therapy of patients with hemoblastosis and concomitant COVID-19 infection in Kazakhstan.


Saparbay J, Kemaykin V, Vildanova R, Karabekov A, Burkitabayev Z. Case series of complex therapy of hemoblastosis in the context of COVID-19. J Clin Med Kaz. 2021.


  • Worldometer, 2020. COVID-19 Coronavirus Pandemic. URL: Accessed October 20, 2020.
  • Kazinform, 2020. COVID-19 Epidemiya koronavirusa. URL: Accessed October 20, 2020.
  • Zhu WJ, Wang J, and He XH, et al (2020) [The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease] Zhonghua Zhong Liu Za Zhi 42(0) E008 PMID; DOI: 10.3760/cma.j.cn112152-20200303-00166
  • Robert Weinkove, Zoe K McQuilten, Jonathan Adler, Meera R Agar, Emily Blyth, et al., «Managing haematology and oncology patients during the COVID‐19 pandemic: interim consensus guidance» Wiley Public Health Emergency Collection 2020 Jun; 212(10): 481–489DOI: 10.5694/mja2.50607
  • G.Curigliano1S.Banerjee2A.Cervantes34M.C.Garassino5P.Garrido6 et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. July 2020. DOI: 10.1016/j.annonc.2020.07.010
  • Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016;35: e418-23. DOI: 10.1200/EDBK_159009. PMID: 27249749. DOI: 10.1200/EDBK_159009
  • National Comprehensive Cancer Network
  • Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K, Repousis P, Missouri-Mentzikof C. Dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients PMID: 17436400
  • Srikanth M, Davies FE, Wu P, et al. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. Eur J Haematol 2008;81:432-436 DOI: 10.1111/j.1600-0609.2008.01131.x
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–405. DOI: 10.1182/blood-2016-03-643544
  • Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21 (3):335-337. DOI:10.1016/S1470-2045(20)30096-6
  • Clinical guidelines of Kazakhstan Health Care Ministry “Coronovirus infection treatment”- 10-th edition with changes from 15.07.2020.